CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...
The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.
A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results